Background
==========

S-phase kinase-associated protein 2 (Skp2), a mammalian F-box protein, displays S-phase-promoting function, through ubiquitin-mediated proteolysis of the CDK inhibitor p27. Skp2 has been shown to regulate cellular proliferation by targeting several cell cycle-regulated proteins for ubiquitination and degradation. Skp2 has also been demonstrated to display an oncogenic function since its overexpression has been observed in many human cancers \[[@B1]\]. High expression of Skp2 was reported to correlate with reduced overall survival in patients with myxofibrosarcoma \[[@B2],[@B3]\]. Di Vizio et al. \[[@B4]\] found that Skp2 expression correlates with poor prognosis in gastrointestinal stromal tumors (GIST). Oliveira found that Skp2 expression is associated with cell proliferation and a worse prognosis in 182 soft tissue sarcomas \[[@B5]\]. In a previous study we showed that high expression of Skp2 was a negative prognostic factor for DSS \[[@B6]\]. Interestingly, this correlation was statistically significant in females only, not in males. This may be related to differences in expression of sexual hormone receptors (ER and PGR) in male and female STS patients \[[@B7],[@B8]\]. In previous studies, we have shown the prognostic value of female steroid hormone receptors in STSs, both alone and in coexpression with TGF-β, fascin and Akt isoforms \[[@B7]-[@B9]\]. Such prognostic impact is not surprising, since both ER and PGR regulate growth and cell differentiation upon ligand-dependent and ligand-independent activation and are in essence growth factors. However, the prognostic significance of Skp2 related to ER and PGR in STS has not been sufficiently investigated.

The purpose of this study is to clarify the prognostic significance of expression of Skp2 related to age, gender and female steroid hormone receptors (ER and PGR) in non-gastrointestinal stromal tumor (non-GIST) STS. To achieve this, we analyzed the expression of these markers in 193 patients with non-GIST STS in relation to demographic and other clinicopathological variables. Our major hypothesis is that a different prognostic significance of Skp2 in men and women exists and is related to diverse gender expressions of ER and PGR.

Methods
=======

Primary tumor tissues from patients diagnosed with STS at the University Hospital of North Norway (UNN) from 1973 to 2006 and the Hospitals of Arkhangelsk region, Russia, were used in this retrospective study. In total, 496 potentially suitable patient records were identified from the hospitals' databases. Of these, 247 patients were excluded due to missing clinical data (n = 86) or inadequate material for histological examination (n = 161). In addition, 33 were excluded because of metastasis at the time of the diagnosis, 13 were excluded because they had no surgery, and 10 patients had both metastasis and no surgery, leaving a total of 193 patients eligible for this study. This report includes data for 131 Norwegian patients and 62 Russian patients followed until September 2009. The median follow-up was 38 (range 0--392) months. Complete demographic and clinical data were collected retrospectively. Formalin-fixed and paraffin-embedded tumor specimens were obtained from the archives of the Departments of Pathology at UNN and Arkhangelsk. The tumors were graded according to the French Fédération Nationales des Centres de Lutte Contre le Cancer (FNCLCC) system \[WHO Tumors of Soft Tissue and bone, 2002\]. Wide resection margins were defined as wide local resection with free microscopic margins or amputation of the affected limb or organ. Non-wide resection margins were defined as either marginal or intralesional resection margins.

Microarray construction
-----------------------

Two pathologists (AV and SWS) reviewed the histology of all soft tissue sarcoma cases. Tissue microarrays (TMAs) were constructed for high-throughput molecular pathology research \[[@B10]\]. The most representative areas of viable tumor cells were carefully selected and marked on the hematoxylin and eosin (HE) slides for the corresponding donor blocks and sampled for the tissue microarray collector blocks. The TMAs were assembled using a tissue-arraying instrument (Beecher Instruments).

Studies suggest that punching multiple 0.6 mm cores from different regions captures the heterogeneity of the tumors more accurately than a single 2 to 4 mm core \[[@B11]\]. We therefore chose to use two 0.6-mm cores of viable neoplastic tissue. After reviewing all original sections of the tumor and taking heterogeneity into consideration, the two cores were selected to be as representative as possible (different areas). To include all core samples, 12 tissue array blocks were constructed. Multiple 4-μm sections were cut with a Micron microtome (HM355S) and stained with specific antibodies for immunohistochemistry (IHC).

Immunohistochemistry (IHC)
--------------------------

The applied antibodies were subjected to in-house validation by the manufacturer of IHC analysis on paraffin-embedded material. All staining was performed in the Ventana Benchmark XT automated slide stainer (Ventana Medical System, Illkirch, France). Before staining, the sections were incubated over night at 60 degrees Celsius. Tissue sections were incubated with primary mouse monoclonal antibodies recognizing Skp2 (Zymed, catalog number 18--0307, 1:10), ER (Ventana, catalog number 790--4324, ready to use) and PGR (Ventana, catalog number 790--4296). The incubation periods were 40 minutes for Skp2, 32 minutes for ER and 24 min for PGR. This was followed by application of liquid diaminobenzidine as substrate-chromogen, yielding a brown reaction product at the site of the target antigen (Ventana iView DAB Detection Kit, catalog number 760--091). iVIEW DAB Detection Kit is an indirect biotin streptavidin system for detecting mouse and rabbit primary antibodies. The DAB chromogen produces a dark brown precipitate that is readily visualized by light microscopy. All reagents are provided pre-diluted by the manufacturer for use in Ventana Benchmark XT. Finally, slides were counterstained with hematoxylin to visualize the nuclei. For each antibody, including negative controls, all TMA staining were performed in a single experiment. In the TMA we also used cores from carcinomas and normal tissue as positive and negative controls.

Scoring of IHC
--------------

The ARIOL imaging system (Genetix, San Jose, CA) was used to scan the slides for antibody staining of the TMAs. The specimens were scanned at a low resolution (1.25×) and a high resolution (20×) using an Olympus BX 61 microscope with an automated platform (Prior). The slides were loaded in the automated slide loader (Applied Imaging SL 50). Representative and viable tissue sections were scored manually on a computer screen semi-quantitatively for nuclear and/or cytoplasmic staining. The expression of Skp2, ER and PGR was scored as: 0, negative; 1, weak; 2, intermediate and 3, strong (Figure [1](#F1){ref-type="fig"}). The score for each patient was based on the mean scoring of cores from one or several biopsies. To achieve maximal reproducibility in all cases, every staining was dichotomized (negative and positive expression). Positive expression was defined as mean score \> 0. All samples were anonymized and independently scored by two pathologists (AV and SWS). In case of disagreement, the slides were re-examined and the observers reached a consensus. When assessing a variable for a given score, the scores of the other variables and the outcome were hidden from the observers.

![**Pictures of cores.** Immunohistochemistry microscopic pictures of tissue micro array of soft tissue sarcoma representing different expression of Skp2 and ER. (**A**) Skp2 low score; (**B**) Skp2 high score; (**C**) ER low score; (**D**) ER high score; (**E**) PGR low score; (**F**) PGR high score; Original magnification ×100 and ×400.](1472-6890-13-9-1){#F1}

Statistical methods
-------------------

All statistical analysis was performed using the statistical package SPSS (Chicago, IL), version 18. The IHC scores from each observer were compared for inter-observer reliability by use of a two-way random effects model with absolute agreement definition. The intra-class correlation coefficient (reliability coefficient) was obtained from these results.

Chi-square and Fisher exact tests were used to examine the association between molecular marker expression and various clinicopathological parameters. Univariate analyses were done using the Kaplan-Meier method, and statistical significance between survival curves was assessed by the log rank test. Disease-specific survival (DSS) was determined from the date of histologically confirmed STS diagnosis. Correlation of marker expression was done using the Pearson correlation (2-tailed) at the 0.05 and 0.01 levels.

Multivariate analysis was carried out using the Cox proportional hazards model to assess the specific impact of each pre-treatment variable on survival in the presence of other variables. Variables of significant value from the univariate analysis were entered into the Cox regression analysis. Probability for stepwise entry and removal was set at 0.05 and 0.10, respectively. The significance level used was p \< 0.05.

Consent
-------

The National Cancer Data Inspection Board and The Regional Committee for Research Ethics (REK nord) approved the study. The material was collected from our approved biobank for paraffin embedded material and slides. The Regional Committee approved that written consent from the patients for their information to be stored in the hospital database and used for research was not needed because most of the material was more than 10 years old, and most of the patients being dead. The ethics committee specifically waived the need for consent. Data were analyzed anonymously.

Results
=======

Clinicopathological variables
-----------------------------

Demographic, clinical, and histopathological variables are shown in Table [1](#T1){ref-type="table"}. Patient age ranged from 0--89 years (mean 55 years), and 42% of patients (81/193) were male. Treatment for all patients included surgery: 104 patients received surgery only; 52 patients received surgery and radiotherapy; 28 patients received surgery and chemotherapy; 9 patients received surgery, radiotherapy and chemotherapy. The 5-year survival for patients with wide and non-wide resection margins was 66% and 46% respectively, Table [1](#T1){ref-type="table"}.

###### 

Prognostic clinicopathological variables as predictors for disease-specific survival of soft tissue sarcomas (univariate analysis, log rank test), N = 193

  **Characteristic**             **Patients (n)**   **Patients (%)**   **Median survival (months)**   **5-Year survival (%)**    **P**
  ----------------------------- ------------------ ------------------ ------------------------------ ------------------------- ---------
  **Age**                                                                                                                           
  \<20 years                            17                 9                       190                          47               0.064
  20--59 years                          85                 44                      235                          63                  
  ≥60 years                             91                 47                      111                          51                  
  **Gender**                                                                                                                        
  Male                                  81                 42                      235                          60               0.087
  Female                               112                 58                      180                          53                  
  **Nationality**                                                                                                                   
  Norwegian                            131                 68                      228                          62               0.005
  Russian                               62                 32                       81                          44                  
  **Histology**                                                                                                                     
  Pleomorphic sarcoma                   57                 30                       52                          45               0.031
  Leiomyosarcoma                        47                 24                       89                          64                  
  Liposarcoma                           32                 17                       NR                          71                  
  MF/MFT                                16                 8                       123                          56                  
  Angiosarcoma                          8                  4                        10                          38                  
  Rhabdomyosarcoma                      9                  5                        NR                          67                  
  MPNST                                 9                  5                        NR                          56                  
  Synovial sarcoma                      12                 6                        31                          30                  
  Other STS                             3                  2                        NR                          \-                  
  **Tumor localization**                                                                                                            
  Extremities                           78                 40                      201                          56               0.922
  Trunk                                 37                 19                      214                          53                  
  Retroperitoneum                       27                 14                      135                          51                  
  Head/Neck                             13                 7                       191                          58                  
  Visceral                              38                 20                      202                          62                  
  **Tumor size**                                                                                                                    
  \<5 cm                                57                 30                      257                          69               0.026
  5--9 cm                               73                 38                      183                          54                  
  ≥10 cm                                61                 32                      127                          48                  
  Missing                               2                  1                                                                        
  **Malignancy grade FNCLCC**                                                                                                       
  1                                     54                 28                       NR                          81              \<0.001
  2                                     76                 39                       80                          55                  
  3                                     63                 33                       28                          36                  
  **Surgical margins**                                                                                                              
  Wide                                  97                 50                      254                          66              \<0.001
  Non-wide                              96                 50                      128                          46                  
  **Chemotherapy**                                                                                                                  
  No                                   156                 81                      207                          57               0.669
  Yes                                   37                 19                      180                          51                  
  **Radiotherapy**                                                                                                                  
  No                                   132                 68                      216                          58               0.190
  Yes                                   61                 32                      152                          52                  

*Abbreviations: MF/MFT*, malignant fibroblastic/myofibroblastic tumors; *MPNST*, malignant peripheral nerve sheath tumor; *STS*, soft tissue sarcomas; *NR*, not reached; *NOS*, non specified.

Inter-observer variability
--------------------------

There was good scoring agreement between the two investigating pathologists. The IHC scores from each observer were compared using a two-way random effects model with absolute agreement definition. The intra-class correlation coefficients (reliability coefficients, r) obtained from these results were 0.94 for Skp2 (p \< 0.001), 0.92 for ER (p \< 0.001) and 0.96 for PGR (p \< 0.001).

Univariate analyses
-------------------

Nationality, histology, tumor size, malignancy grade and surgical margins were all significant indicators for disease-specific survival (DSS) in univariate analyses (Table [1](#T1){ref-type="table"}). Table [2](#T2){ref-type="table"} shows the percentage of high expression of ER, PGR and Skp2 in the different histological subtypes. Chi-square test showed no differences in overall expression of ER, PGR and Skp2 with respect to the different histological subtypes.

###### 

Percentage of high expression of ER, PGR and Skp2 in the different histological subtypes N = 193

  **Histology**          **N**   **ER (%)\***   **PGR (%)\*\***   **Skp2 (%)\*\*\***
  --------------------- ------- -------------- ----------------- --------------------
  Pleomorphic sarcoma     57          40              26                  37
  Leiomyosarcoma          47          50              43                  40
  Liposarcoma             32          35              23                  21
  MF/MFT                  16          27              29                  36
  Angiosarcoma             8          25              13                  29
  Rhabdomyosarcoma         9          50              56                  67
  MPNST                    9          11              11                  44
  Synovial sarcoma        12          40              27                  50
  Other STS                3          67              33                  67
  Total                   193         39              30                  38

\* Chi 8.516, p = 0.385.

\*\* Chi 10.238, p = 0.249.

\*\*\* Chi 8.596, p = 0.377.

*Abbreviations: MF/MFT*, malignant fibroblastic/myofibroblastic tumors; *MPNST*, malignant peripheral nerve sheath tumor.

Chi-square test showed no differences in percentage of high expression of ER, PGR and Skp2 in the different histological subtypes.

In univariate analyses, increased expression of Skp2 (p = 0.050) correlated significantly with reduced DSS, (Table [3](#T3){ref-type="table"} and Figure [2](#F2){ref-type="fig"}). No such relationship was apparent for ER and PGR when males and females were combined in one group.

![**Survival plots ER and PGR.** Disease-specific survival curves for high and low expression of ER and PGR in male (N = 81) and female (N = 112) patients with soft tissue sarcomas.](1472-6890-13-9-2){#F2}

###### 

Expression of markers, gender and their prediction for disease-specific survival in patients with soft tissue sarcomas (univariate analysis; log-rank test), All = 193, Males = 81, Females = 112

  **Marker expression**    **Patients (n)**   **Patients (%)**   **Median survival (months)**   **5-year survival (%)**   **P**
  ----------------------- ------------------ ------------------ ------------------------------ ------------------------- -------
  **Skp2, all**                                                                                                              
  Low                            109                 56                       NR                          63              0.050
  High                            67                 45                       59                          50                 
  Missing                         17                 9                                                                       
  **Skp2, men**                                                                                                              
  Low                             50                 62                       NR                          63              0.577
  High                            23                 28                       67                          61                 
  Missing                         8                  10                                                                      
  **Skp2, women**                                                                                                            
  Low                             59                 53                       NR                          63              0.066
  High                            44                 39                       49                          44                 
  Missing                         9                  8                                                                       
  **ER, all**                                                                                                                
  Low                            112                 58                      123                          57              0.725
  High                            72                 67                       91                          57                 
  Missing                         9                  5                                                                       
  **ER, men**                                                                                                                
  Low                             49                 60                       NR                          69              0.089
  High                            29                 36                       58                          49                 
  Missing                         3                  4                                                                       
  **ER, women**                                                                                                              
  Low                             63                 56                       57                          47              0.041
  High                            43                 38                       NR                          62                 
  Missing                         6                  5                                                                       
  **PGR, all**                                                                                                               
  Low                            132                 68                       NR                          62              0.101
  High                            57                 30                       52                          46                 
  Missing                         4                  2                                                                       
  **PGR, men**                                                                                                               
  Low                             64                 79                       NR                          69              0.010
  High                            15                 19                       41                          33                 
  Missing                         2                  2                                                                       
  **PGR, women**                                                                                                             
  Low                             68                 61                       80                          55              0.832
  High                            42                 38                       74                          51                 
  Missing                         2                  2                                                                       

*Abbreviations: NR*, not reached.

In subgroup analyses (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}), increased PGR expression in men (p = 0.010) and in patients older than 60 years (p = 0.043) was associated with a reduced DSS. Increased ER expression in women was associated with longer DSS (p = 0.041). High expression of ER were associated with favorable survival in patients with rhabdomyosarcoma (N = 9, p = 0.040). High expression of ER was associated with poor survival in patients with synovial sarcoma (N = 12, p = 0.010). There were no significant differences in survival according to high or low expression of Skp2 in any of the histological subtypes (data not shown).

###### 

Expression of markers, age and their prediction for disease-specific survival in patients with soft tissue sarcomas (univariate analysis; log-rank test)

  **Marker expression**           **Patients (n)**   **Patients (%)**   **Median survival (months)**   **5-Year survival (%)**   **P**
  ------------------------------ ------------------ ------------------ ------------------------------ ------------------------- -------
  **Skp2, \<60 years, N = 99**                                                                                                      
  Low                                    52                 53                       NR                          71              0.074
  High                                   38                 38                       67                          56                 
  Missing                                9                  9                                                                       
  **Skp2, ≥60 years, N = 94**                                                                                                       
  Low                                    57                 61                       80                          57              0.188
  High                                   29                 31                       36                          42                 
  Missing                                8                  9                                                                       
  **ER, \<60 years, N = 99**                                                                                                        
  Low                                    55                 56                      127                          59              0.197
  High                                   40                 40                       NR                          67                 
  Missing                                4                  4                                                                       
  **ER, ≥60 years, N = 94**                                                                                                         
  Low                                    57                 61                       80                          55              0.293
  High                                   32                 34                       52                          44                 
  Missing                                5                  5                                                                       
  **PGR, \<60 years, N = 99**                                                                                                       
  Low                                    63                 64                       NR                          67              0.488
  High                                   34                 34                       NR                          55                 
  Missing                                2                  2                                                                       
  **PGR, ≥60 years, N = 94**                                                                                                        
  Low                                    69                 73                       91                          57              0.043
  High                                   23                 24                       39                          32                 
  Missing                                2                  2                                                                       

*Abbreviations: NR*, not reached.

In patients with low expression of ER (N = 112), men had better 5-year survival (69%) compared to women (47%, p = 0.002), while there were no differences (p = 0.376) between men and women in patients with high expression of ER (N = 72). In patients with low expression of PGR (N = 132), men had better 5-year survival (69%) compared to women (55%, p = 0.013), while there were no differences (p = 0.271) between men and women in patients with high expression of PGR (N = 57). There were no differences in survival between men and women in univariate analyses of patients with low (N = 109, p = 0.529) or high (N = 67, p = 0.233) expression of Skp2 (data not shown).

In co-expression analyses (Table [5](#T5){ref-type="table"}) Skp2 negative / ER negative profile was associated with longer DSS (p = 0.049). In women a Skp2 positive and ER negative profile was associated with reduced DSS (p = 0.021), Table [5](#T5){ref-type="table"} and Figure [3](#F3){ref-type="fig"}. In men a double negative ER/PGR profile was associated with longer DSS (p = 0.013) while in women a double positive ER/PGR was associated with longer DSS (p = 0.001). In patients younger than 60 years the combination ER negative and PGR positive was associated with shorter DSS. In the whole cohort of patients a triple positive expression of ER, PGR and Skp2 was associated with longer DSS (p = 0.005), Figure [3](#F3){ref-type="fig"}. Triple negative expression of ER, PGR and Skp2 was also associated with longer DSS, but not statistically significant (p = 0.068), Figure [3](#F3){ref-type="fig"}. ER negative / PGR positive co-expression was associated with shorter DSS regardless of Skp2 expression, Table [6](#T6){ref-type="table"}.

![**Survival plots co-expression.** Disease-specific survival curves for co-expression of Skp2, ER or PGR in males (N = 81), females (N = 112) and co-expression of ER and PGR in Skp2 negative (N = 109) and Skp2 positive (N = 67) patients.](1472-6890-13-9-3){#F3}

###### 

Co-expression of Skp2/ER, Skp2/PGR and their prediction for disease-specific survival in patients with soft tissue sarcomas (univariate analysis; log-rank test), All = 193, Men = 81, Women = 112

  **Co-expression**        **Patients (n)**   **Patients (%)**   **Median survival (months)**   **5-Year survival (%)**   **P**
  ----------------------- ------------------ ------------------ ------------------------------ ------------------------- -------
  **Skp2 / ER, all**                                                                                                         
  Low/low                         66                 34                       NR                          67              0.049
  Low/high                        39                 20                       91                          59                 
  High/low                        35                 18                       57                          44                 
  High/high                       30                 16                       NR                          58                 
  Missing                         23                 12                                                                      
  **Skp2 / ER, men**                                                                                                         
  Low/low                         33                 41                       NR                          72              0.427
  Low/high                        16                 20                       37                          50                 
  High/low                        11                 14                       NR                          72                 
  High/high                       11                 14                       63                          58                 
  Missing                         10                 12                                                                      
  **Skp2 / ER, women**                                                                                                       
  Low/low                         33                 29                      127                          61              0.021
  Low/high                        23                 21                       91                          65                 
  High/low                        24                 21                       31                          32                 
  High/high                       19                 17                       NR                          58                 
  Missing                         13                 12                                                                      
  **Skp2 / PGR, all**                                                                                                        
  Low/low                         80                 41                       NR                          71              0.056
  Low/high                        25                 13                       54                          46                 
  High/low                        40                 21                       59                          49                 
  High/high                       27                 14                       67                          51                 
  Missing                         21                 11                                                                      
  **Skp2 / PGR, men**                                                                                                        
  Low/low                         41                 51                       NR                          73              0.141
  Low/high                        7                  9                        26                          29                 
  High/low                        18                 22                       NR                          61                 
  High/high                       5                  6                        67                          60                 
  Missing                         10                 12                                                                      
  **Skp2 / PGR, women**                                                                                                      
  Low/low                         39                 35                       NR                          68              0.234
  Low/high                        18                 16                       75                          54                 
  High/low                        22                 20                       29                          39                 
  High/high                       22                 20                       57                          49                 
  Missing                         11                 10                                                                      

*Abbreviations: NR*, not reached.

###### 

Co-expression of ER/PGR and their prediction for disease-specific survival in patients with soft tissue sarcomas (univariate analysis; log-rank test)

  **Co-expression**                   **Patients (n)**   **Patients (%)**   **Median survival (months)**   **5-year survival (%)**    **P**
  ---------------------------------- ------------------ ------------------ ------------------------------ ------------------------- ---------
  **ER / PGR, all, N = 193**                                                                                                             
  Low/low                                    84                 44                       NR                          69              \<0.001
  Low/high                                   26                 13                       38                          24                  
  High/low                                   41                 21                       62                          52                  
  High/high                                  31                 16                       NR                          64                  
  Missing                                    11                 6                                                                        
  **ER / PGR, men, N = 81**                                                                                                              
  Low/low                                    39                 48                       NR                          79               0.013
  Low/high                                   9                  11                       41                          33                  
  High/low                                   23                 28                       63                          53                  
  High/high                                  6                  7                        37                          33                  
  Missing                                    4                  5                                                                        
  **ER / PGR, women, N = 121**                                                                                                           
  Low/low                                    45                 40                       89                          59               0.001
  Low/high                                   17                 15                       31                          19                  
  High/low                                   18                 16                       29                          50                  
  High/high                                  25                 22                       NR                          72                  
  Missing                                    7                  6                                                                        
  **ER / PGR, \<60 years, N = 99**                                                                                                       
  Low/low                                    41                 41                       NR                          72               0.001
  Low/high                                   13                 13                       31                          23                  
  High/low                                   19                 19                       NR                          58                  
  High/high                                  21                 21                       NR                          76                  
  Missing                                    5                  5                                                                        
  **ER / PGR, ≥60 years, N = 94**                                                                                                        
  Low/low                                    43                 46                       NR                          64               0.052
  Low/high                                   13                 14                       39                          26                  
  High/low                                   22                 23                       58                          47                  
  High/high                                  10                 11                       37                          40                  
  Missing                                    6                  6                                                                        
  **ER / PGR, Skp2 low, N = 109**                                                                                                        
  Low/low                                    55                 50                       NR                          76               0.068
  Low/high                                   9                  8                        68                          25                  
  High/low                                   23                 21                       91                          61                  
  High/high                                  16                 15                       75                          56                  
  Missing                                    6                  6                                                                        
  **ER / PGR, Skp2 high, N = 67**                                                                                                        
  Low/low                                    21                 31                       89                          55               0.005
  Low/high                                   14                 21                       31                          29                  
  High/low                                   17                 25                       29                          42                  
  High/high                                  13                 19                       NR                          77                  
  Missing                                    2                  3                                                                        

*Abbreviations: NR*, not reached.

Taking into consideration the possible distortion of results by gender-related sarcomas (i.e. leiomyosarcoma in uterus) we have attempted to exclude these sarcomas and recalculate all analyses. There were no significant differences in the results compared to those obtained without exclusion of gender-related sarcomas (data not shown).

Multivariate analyses
---------------------

Significant demographic, clinicopathological and expression variables from the univariate analyses were entered into the multivariate Cox regression analysis (Table [7](#T7){ref-type="table"}). In the multivariate analyses, age (p = 0.012), malignancy grade (p \< 0.001), wide resection margins (p = 0.010), ER negative / PGR positive co-expression (p = 0.002) and ER positive / PGR negative co-expression (p = 0.015) were independent negative prognostic factors for DSS. In women, expression of Skp2 (p = 0.006) was associated with reduced DSS. In women, tumor size (p = 0.020) and nationality (p = 0.014) were independent prognostic factors for DSS, Table [7](#T7){ref-type="table"}. In multivariate analyses co-expression of Skp2/ER or Skp2/PGR were not stronger prognosticators for DSS than single expression of Skp2, ER and PGR (data not shown).

###### 

Results of Cox regression analysis summarizing prognostic factors in patients with soft tissue sarcomas

                                 **All patients, N = 193**   **Men, N = 81**   **Women, N = 112**                                                     
  ----------------------------- --------------------------- ----------------- -------------------- ------- ------------ --------- ------ ------------ ---------
  **Age**                                                                                                                                                  
  0--59 years                              1.00                                                     1.00                           1.00                    
  ≥60 years                                1.84                 1.15-2.95            0.012          1.69    0.65-4.41     0.282    1.51   0.83-2.77     0.179
  **Nationality**                                                                                                                                          
  Norwegian                                1.00                                                     1.00                           1.00                    
  Russian                                  1.49                 0.88-2.52            0.143          1.39    0.41-4.66     0.598    2.51   1.20-5.21     0.014
  **Tumor size**                                                                                                                                           
  \<5 cm                                   1.00                                     0.138\*         1.00                 0.668\*   1.00                0.020\*
  5--9 cm                                  1.47                 0.79-2.73            0.226          1.68    0.54-5.25     0.372    1.71   0.77-3.77     0.187
  ≥10 cm                                   1.91                 1.01-3.60            0.047          1.32    0.40-4.39     0.652    3.14   1.38-7.15     0.006
  **Malignancy grade FNCLCC**                                                                                                                              
  1                                        1.00                                    \<0.001\*        1.00                 \<0.001   1.00                0.004\*
  2                                        2.72                 1.36-5.46            0.005          3.07    0.86-10.96    0.084    4.33   1.76-10.67    0.001
  3                                        4.61                 2.26-9.40           \<0.001         15.47   4.36-54.97   \<0.001   4.23   1.64-10.89    0.003
  **Resection margins**                                                                                                                                    
  Wide                                     1.00                                                     1.00                           1.00                    
  Non-wide                                 1.87                 1.16-3.02            0.010          7.69    2.67-22.16   \<0.001   0.81   0.42-1.54     0.512
  **Skp2**                                                                                                                                                 
  Low                                      1.00                                                     1.00                           1.00                    
  High                                     1.48                 0.87-2.52            0.151          0.46    0.19-1.12     0.088    2.52   1.31-4.85     0.006
  **ER / PGR**                                                                                                                                             
  Low/low                                  1.00                                     0.006\*         1.00                 0.004\*   1.00                0.216\*
  Low/high                                 2.64                 1.43-4.85            0.002          4.99    1.31-18.97    0.018    1.91   0.89-4.11     0.097
  High/low                                 2.07                 1.15-3.73            0.015          8.35    2.55-27.36   \<0.001   1.76   0.79-3.93     0.170
  High/high                                1.16                 0.57-2.38            0.682          4.50    0.96-21.13    0.056    0.92   0.36-2.35     0.868

\* Overall significance as a prognostic factor. The difference between the individual p-value and total p-value in the multivariate analysis is relevant in cases where there are more than two categories for a given variable. Overall p-value is calculated based on a general assessment of all categories for the given variable, but the individual p-value only calculates the significance of a given category versus the reference category.

Discussion
==========

In this large-scale study, we evaluated the prognostic significance of expression of Skp2 related to age, gender, ER and PGR in 193 STS patients. Our hypothesis was confirmed. We found diverse prognostic DSS impacts from gender related expression of Skp2, ER, PGR and DSS in STS. In men, but not women, an ER positive/PGR negative co-expression profile was an independent negative prognostic factor for DSS. In women, but not men, high expression of Skp2 was associated with reduced DSS. High expression of ER reduced the negative impact of Skp2 in women. While women with the Skp2 positive / ER positive phenotype had favorable survival, women with the Skp2 positive / ER negative phenotype had poor survival. To the best of our knowledge, this is the first prognostic evaluation of Skp2 related to the female hormone receptors ER and PGR in STS.

Expression of ER and PGR is a routinely investigated indicator of endocrine therapy success in breast cancer \[[@B12],[@B13]\] and a modest, but significantly better overall survival of anti-estrogen receptor therapy has been documented \[[@B14]\]. ER and PGR are also reported to be positive prognosticators of uterine leiomyosarcomas \[[@B15]\]. However, extra-uterine sarcomas have barely been explored in this context. The distribution and prognostic value of expression of these steroid hormone receptors in STS are therefore of great scientific interest. In our study, in the univariate analyses, ER showed a significantly favorable influence on survival in female patients, but not in males. PGR was an unfavorable prognosticator for men, but not for women. In multivariate analysis ER positive / PGR negative co-expression is an independent negative prognostic factor for DSS in males, but not in females.

We have modified the Allred score for STS and used 1% positivity as cut-off value \[[@B7],[@B16]\]. The strong and moderate (score 3 and 2, respectively) hormone receptor expression occurred mostly in sarcomas of uterus, pelvis and breast, while the weak (score 1) expression of both ER and PGR was surprisingly evenly distributed among location, gender and age. Generally, 39% of the tumors expressed ER and 30% expressed PGR in our material. Roughly half of the patients expressed at least one of these receptors. The findings are in partial agreement with findings of Chaudhuri et al. \[[@B17]\] who found ER to be positive in 24% of STS.

Huang et al. suggested that the therapeutic strategies designed to reduce Skp2 may play an important clinical role in treatment of breast cancer cells, especially ER/HER2 negative breast cancers \[[@B18]\]. Voduc et al. found cyclin E and Skp2 to be prognostic for breast cancer-specific survival in univariate analyses. Double positive expression of cyclin E / Skp2 was associated with young age at diagnosis, grade 3 tumors, ER-negative status and HER2 negative status \[[@B19]\]. Zheng et al. found that higher levels of Skp2 were detected more frequently in ER-negative breast cancer tumors and tumors metastatic to the axillary lymph nodes \[[@B20]\]. Signoretti et al. also found that higher levels of Skp2 are present more frequently in ER-negative tumors than in ER-positive cases. The subset of Skp2 positive / ER negative breast carcinomas were also characterized by high tumor grade and HER2 negative \[[@B21]\]. In our material, the five year DSS in Skp2 positive / ER negative women with STS was 32% compared to 58% in Skp2 positive / ER positive women (P = 0.021).

In our previous work we have shown that ER and PGR expression possess variable prognostic significance depending on gender, both *per se* and in co-expression with TGF-β, fascin and Akt isoforms \[[@B7]-[@B9]\]. In the present study, the prognostic diversity of Skp2, ER and PGR in men and women was seen in the different co-expression profiles: female patients with Skp2 positive / ER negative profile had decreased survival rates. For men, the Skp2 negative / ER negative profile was the most favorable phenotype. PGR expression in men, but not women, was associated with a shorter DSS. ER expression in women, but not men, was associated with a longer DSS. The ER negative / PGR positive profile was a significantly unfavorable factor for the whole patient cohort both in univariate and multivariate analysis. Interestingly, such a profile occurred in only 2% of patients in one large-scale study based on 3000 breast cancer cases \[[@B22]\], while in our STS study this profile was seen in 13% of tumors.

The data collection introduced problems in identifying adequate numbers of similar patients with similar tumors and with the same treatment traditions. These are well known problems when conducting STS studies. Our findings are in large hypothesis generating, and to be more conclusive future STS studies must be based on large, multi-institutional and multinational studies with possibilities to establish adequately sized STS patient cohorts of homogenous tumor groups. However, all tumors investigated herein had mesenchymal derivation and belong to the same generic group.

Conclusions
===========

In conclusion, there were different prognostic impacts of expression of Skp2, ER, PGR and DSS in male and female patients with STS. In men, but not in women, ER positive / PGR negative co-expression was an independent negative prognostic factor for DSS. In women, but not in men, expression of Skp2 was associated with reduced DSS.
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